Efficacy of high-definition transcranial direct current stimulation on craving in substance use disorders: a systematic review and meta-analysis.

J Addict DisApr 18, 2026 (epub)
Clinical ResearchPsychiatry

Priyanka Saha, Jadeer K Muhammed, Pinki Sevda et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the efficacy of high-definition transcranial direct current stimulation (HD-tDCS) on craving in substance use disorders, analyzing three randomized controlled trials with a total of 138 participants. The results indicated a moderate reduction in craving compared to sham stimulation, with a pooled effect size of g = -0.596 (95% CI: -1.039 to -0.152; p = 0.008).

Key findings

  • Pooled analysis showed a moderate reduction in craving with HD-tDCS (g = -0.596; p = 0.008).
  • The analysis included three RCTs with a total of 138 participants.
  • Risk of bias in the included studies ranged from low to moderate.
  • Minimal heterogeneity was observed (I 2 = 0%).

Why it matters

Understanding effective interventions for craving in substance use disorders is crucial for preventing relapse. This study suggests that HD-tDCS may be a promising noninvasive option to help manage cravings, potentially improving treatment outcomes.

What to keep in mind

The small number of studies and limited sample sizes restrict the generalizability of the findings.

Source

Published in J Addict Dis. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.